Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66,399,673
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
45,934,145
-
Shares change
-
-2,876,768
-
Total reported value, excl. options
-
$190,627,988
-
Value change
-
-$18,795,957
-
Put/Call ratio
-
0%
-
Number of buys
-
38
-
Number of sells
-
-62
-
Price
-
$4.15
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q2 2022
119 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q2 2022.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45,934,145 shares
of 66,399,673 outstanding shares and own 69% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (6,364,094 shares), NEA Management Company, LLC (4,912,306 shares), RA CAPITAL MANAGEMENT, L.P. (4,871,067 shares), FEDERATED HERMES, INC. (4,395,600 shares), BAKER BROS. ADVISORS LP (4,125,062 shares), GOLDMAN SACHS GROUP INC (3,160,386 shares), VANGUARD GROUP INC (2,149,726 shares), JANUS HENDERSON GROUP PLC (2,080,077 shares), FRANKLIN RESOURCES INC (1,779,430 shares), and ALKEON CAPITAL MANAGEMENT LLC (1,500,000 shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.